MARKET

AMLX

AMLX

Amylyx Pharmaceuticals
NASDAQ
12.00
-0.19
-1.56%
After Hours: 12.00 0 0.00% 16:10 12/30 EST
OPEN
12.22
PREV CLOSE
12.19
HIGH
12.43
LOW
11.92
VOLUME
1.37M
TURNOVER
--
52 WEEK HIGH
16.96
52 WEEK LOW
2.600
MARKET CAP
1.32B
P/E (TTM)
-6.6681
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AMLX last week (1222-1226)?
Weekly Report · 1d ago
Friday 12/26 Insider Buying Report: AMLX, MAIA
NASDAQ · 4d ago
How Investors Are Reacting To Amylyx Pharmaceuticals (AMLX) Early AMX0114 Safety Data And Insider Buying
Simply Wall St · 4d ago
Director Karen Firestone Acquires Common Shares of Amylyx Pharmaceuticals Inc
Reuters · 6d ago
Weekly Report: what happened at AMLX last week (1215-1219)?
Weekly Report · 12/22 09:02
Amylyx price target lowered to $15 from $16 at BofA
TipRanks · 12/19 14:11
Bank of America Securities Keeps Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
TipRanks · 12/19 10:55
After-Hours Gainers: A Quiet Session With A Standout Biotech Surge
NASDAQ · 12/17 04:29
More
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.

Webull offers Amylyx Pharmaceuticals Inc stock information, including NASDAQ: AMLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMLX stock methods without spending real money on the virtual paper trading platform.